Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $21.8600 (-2%) ($21.0000 - $22.5300) on Wed. Nov. 11, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.13% (three month average) | RSI | 72 | Latest Price | $21.8600(-2%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 1.1% a day on average for past five trading days. | Weekly Trend | FOLD advances 8.2% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Rotation from value to growth for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(50%) XBI(49%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -1.565% in a week (0% probabilities). VIXM(-28%) VXX(-14%) UUP(-11%) UNG(-5%) IGOV(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.565% (StdDev 3.13%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $21.4(2.15%) | 10 Day Moving Average | $20.15(8.49%) | 20 Day Moving Average | $19.03(14.87%) | To recent high | -2% | To recent low | 69.8% | Market Cap | $5.645b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |